Oral beclomethasone dipropionate as an alternative to systemic steroids in mild to moderate ulcerative colitis not responding to aminosalicylates

Digestive Diseases and Sciences

Volumn 55, Issue 7, 2010, Pages 2002-2007

  Papi, Claudio ^a   Aratari, Annalisa ^a   Moretti, Alessandra ^a   Mangone, Manuela ^a   Margagnoni, Giovanna ^a   Koch, Maurizio ^a   Capurso, Lucio ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Aminosalicylates; Beclomethasone dipropionate; Corticosteroids; Ulcerative colitis

Indexed keywords

BECLOMETASONE DIPROPIONATE; C REACTIVE PROTEIN; CORTICOSTEROID; MESALAZINE;

ACNE; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MOON FACE; PRIORITY JOURNAL; PROBABILITY; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ASPIRIN; BECLOMETHASONE; COHORT STUDIES; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTESTINAL MUCOSA; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROBABILITY; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954427389     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-009-0962-6     Document Type: Article

References (34)

1. MJ Carter AJ Lobo SPL Travis On behalf of the IBD Section of the British Society of Gastroenterology 2004 Guidelines for the management of inflammatory bowel disease in adults Gut 53 Suppl V v1 v16 10.1136/gut.2004.043372 15306569 (Pubitemid 39120096)
2. A Kornbluth DB Sachar 2004 Ulcerative colitis practice guidelines in adults (update) Am J Gastroenterol 99 7 1371 1385 10.1111/j.1572-0241.2004. 40036.x 15233681 (Pubitemid 39062279)
3. SPL Travis EF Stange M Lémann For the European Crohn's and Colitis Organisation (ECCO), et al. 2008 European evidence-based consensus on the management of ulcerative colitis: current management J Crohn's Colitis 2 1 24 62 10.1016/j.crohns.2007.11.002 (Pubitemid 351179488)
4. L Sutherland JK MacDonald 2006 Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis Cochrane Database Syst Rev 19 2 CD000543
5. JK Marshall EJ Irvine 1995 Rectal aminosalicylates therapy for distal ulcerative colitis: a meta-analysis Aliment Pharmacol Ther 9 3 293 300 7654892
6. JK Marshall EJ Irvine 2000 Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis Am J Gastroenterol 95 7 1628 1636 10.1111/j.1572-0241.2000.02180.x 10925961
7. RD Cohen DM Woseth RA Thisted, et al. 2000 A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis Am J Gastroenterol 95 5 1263 1276 10.1111/j.1572-0241.2000. 01940.x 10811338
8. M Safdi M DeMicco C Sninsky, et al. 1997 A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis Am J Gastroenterol 92 10 1867 1871 9382054
9. P Marteau CS Probert S Lindgren, et al. 2005 Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study Gut 54 7 960 965 10.1136/gut.2004.060103 15951542 (Pubitemid 40873909)
10. M Vecchi G Meucci P Gionchetti, et al. 2001 Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study Aliment Pharmacol Ther 15 2 251 256 10.1046/j.1365-2036.2001.00913.x 11148445 (Pubitemid 32142504)
11. M Regueiro EV Loftus Jr AH Steinhart, et al. 2006 Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials Inflamm Bowel Dis 12 10 979 994 10.1097/01.mib.0000231495. 92013.5e 17012969 (Pubitemid 44498287)
12. SPL Travis 2006 Review article: induction therapy for patients with active ulcerative colitis Aliment Pharmacol Ther 15 1 10 16 10.1111/j.1365-2036. 2006.03070.x
13. WA Faubion EV Loftus WS Harmsen, et al. 2001 The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study Gastroenterology 121 255 260 10.1053/gast.2001.26279 11487534
14. GT Ho P Chiam H Drummond, et al. 2006 The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort Aliment Pharmacol Ther 24 319 330 10.1111/j.1365-2036.2006.02974.x 16842459 (Pubitemid 43972900)
15. SE Plevy 2002 Corticosteroid-sparing treatments in patients with Crohn's disease Am J Gastroenterol 97 1607 1617 10.1111/j.1572-0241.2002.05818.x 12135008
16. DM Harris 1975 Some properties of beclomethasone dipropionate and related steroids in man Postgrad Med J 51 20 25 1105513
17. F Manguso A Balzano 2007 Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis Aliment Pharmacol Ther 26 1 21 29 17555418
18. L Biancone P Gionchetti G del Vecchio Blanco, et al. 2007 Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study Dig Liver Dis 39 4 329 337 10.1016/j.dld.2007.01. 012 17347061 (Pubitemid 46432253)
19. P Gionchetti A D'Arienzo F Rizzello Italian BDP Study Group, et al. 2005 Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial J Clin Gastroenterol 39 4 291 297 10.1097/01.mcg.0000155124.74548.61 15758622 (Pubitemid 40393243)
20. A D'Arienzo F Manguso GN Castiglione, et al. 1998 Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone Ital J Gastroenterol Hepatol 30 3 254 257 9759590
21. M Campieri M Cottone F Miglio, et al. 1998 Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis Aliment Pharmacol Ther 12 4 361 366 10.1046/j.1365-2036.1998. 00299.x 9690726 (Pubitemid 28182218)
22. KP Steed G Hooper P Ventura, et al. 1994 The in vivo behaviour of a colonic delivery system. Pharmaceutical Profiles Limited study no. PPL-015. Nottingham, 3rd April 1992 Int J Pharm 112 199 206 10.1016/0378-5173(94)90355-7 (Pubitemid 24319836)
23. M Campieri S Adamo D Valpiani, et al. 2003 Oral beclomethasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicenter randomised study Aliment Pharmacol Ther 17 12 1471 1480 10.1046/j.1365-2036.2003.01609.x 12823149 (Pubitemid 36831438)
24. F Rizzello P Gionchetti A D'Arienzo, et al. 2002 Oral beclomethasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study Aliment Pharmacol Ther 16 6 1109 1116 10.1046/j.1365-2036.2002.01298.x 12030952 (Pubitemid 34680753)
25. D Rachmilewitz 1989 Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial BMJ 298 6666 82 86 10.1136/bmj.298.6666.82 2563951
26. S Travis 2004 Review article: the management of mild to severe acute ulcerative colitis Aliment Pharmacol Ther 20 Suppl. 4 88 92 10.1111/j.1365-2036. 2004.02056.x 15352901
27. SB Hanauer WJ Sandborn A Kornbluth, et al. 2005 Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial Am J Gastroenterol 100 11 2478 2485 10.1111/j.1572-0241.2005.00248.x 16279903
28. SB Hanauer WJ Sandborn C Dallaire, et al. 2007 Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial Can J Gastroenterol 21 12 827 834 18080055
29. SB Hanauer 2006 Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis Aliment Pharmacol Ther 24 Suppl 3 37 40 10.1111/j.1365-2036.2006.03058.x 16961743 (Pubitemid 44326418)
30. W Kruis S Bar-Meir J Feher, et al. 2003 The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine Clin Gastroenterol Hepatol 1 1 36 43 10.1053/jcgh.2003.50006 15017515 (Pubitemid 37254470)
31. AV Safdi RD Cohen 2007 Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates Aliment Pharmacol Ther 26 9 1179 1186 17944732
32. R Bergman M Parkes 2006 Systematic review: the use of mesalazine in inflammatory bowel disease Aliment Pharmacol Ther 23 7 841 855 10.1111/j.1365-2036.2006.02846.x 16573787
33. F Rizzello P Gionchetti R Galeazzi, et al. 2001 Oral beclomethasone dipropionate in patients with mild to moderate ulcerative colitis: a dose-finding study Adv Ther 18 6 261 271 10.1007/BF02850196 11841196
34. G Manes V Imbesi S Ardizzone, et al. 2008 Appropriateness and diagnostic yield of colonoscopy in the management of patients with ulcerative colitis: a prospective study in an open access endoscopy service Inflamm Bowel Dis 14 8 1133 1138 10.1002/ibd.20434 18314901